20-gauge safer than 25-gauge surgery

Article

Patients undergoing 25-gauge vitreoretinal surgery are more likely to experience postoperative serous choroidal effusion and hypotony than patients undergoing 20-gauge procedures.

Patients undergoing 25-gauge vitreoretinal surgery are more likely to experience postoperative serous choroidal effusion and hypotony than patients undergoing 20-gauge procedures, according to a report published in the October issue of Retina.

Saad Shaikh and co-workers from Rollins College and Central Florida Retina Consultants, Florida, US compared complication rates between two groups of 129 eyes treated with primary 25- or 20-gauge vitreoretinal surgery. Average follow-up was 9.1 months and 14.3 months in the 25- and 20-gauge groups, respectively.

The researchers found that both groups had similar rates of intraoperative complications, which were mainly rhematogenous in nature. A total of 46% of patients, in both groups, experienced cataract progression. Eyes treated with 25-gauge procedures, had a significantly higher incidence of postoperative complications; 7.9% developed hypotony and serous choroidal effusions compared with just 1.6% of the 20-gauge treated eyes. Two eyes in the 25-gauge group developed endophthalmitis.

It was the conclusion of the authors that 25-gauge surgery is more likely to result in postoperative complications than 20-gauge surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.